National Research Corporation (NRC), a stalwart in the healthcare information services industry, continues to carve its niche within the healthcare analytics market. With a market capitalization of $435.9 million, NRC is positioned within the healthcare sector, offering a suite of subscription-based solutions that enhance patient and employee experiences. Based in the United States and trading on a major exchange, the company is particularly noted for its robust return on equity (ROE) of 66.87%, a standout metric in its financial profile.
Despite a recent price change of -0.02%, with shares currently priced at $18.90, NRC’s stock has seen a significant rise from its 52-week low of $10.13 to near its high of $19.30. This performance indicates a strong recovery trajectory and positions NRC as a compelling option for investors seeking stability and growth in the volatile healthcare sector.
NRC’s financial health is underscored by its free cash flow of $7.57 million, reflecting its ability to generate cash which can be used for reinvestment, dividend payouts, or reducing debt. With an earnings per share (EPS) of $0.71, the company demonstrates solid profitability even in the face of a -3.40% decline in revenue growth. This decline suggests the company is navigating industry headwinds, possibly due to evolving market demands or competitive pressures.
A significant aspect of NRC’s investment appeal is its attractive dividend yield of 2.75%, backed by a payout ratio of 67.61%. This suggests that NRC is committed to returning value to shareholders while maintaining a balanced approach to reinvestment and growth. For income-focused investors, NRC’s dividend offers a reliable income stream, particularly in a low-interest-rate environment.
Interestingly, NRC currently lacks traditional valuation metrics such as P/E, forward P/E, and PEG ratios. This absence may be attributed to the company’s unique business model or a transitional phase in its financial reporting. However, the absence of analyst ratings, with no buy, hold, or sell recommendations, indicates that NRC may be flying under the radar of institutional investors, presenting a potential opportunity for individual investors to capitalize on undiscovered value.
From a technical perspective, NRC is trading above its 50-day moving average of $16.55 and its 200-day moving average of $14.60, indicating a positive trend. However, the relative strength index (RSI) of 45.45 suggests the stock is neither overbought nor oversold, providing a neutral outlook on its momentum.
NRC’s innovative offerings, such as its AI engine Huey AI, position it at the forefront of healthcare experience management. By leveraging advanced analytics and real-time competitive assessments, NRC empowers healthcare organizations to enhance patient and employee experiences, manage reputations, and optimize brand loyalty.
Founded in 1981 and headquartered in Lincoln, Nebraska, NRC has established a solid foundation and reputation in the healthcare analytics domain. For investors seeking exposure to a company with a strong ROE, consistent cash flow, and a focus on sustainable growth, National Research Corporation presents a notable opportunity amidst the broader healthcare sector’s challenges and transformations.
